nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.182	1	CbGbCtD
Sunitinib—Disseminated intravascular coagulation—Riluzole—amyotrophic lateral sclerosis	0.00624	0.0304	CcSEcCtD
Sunitinib—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.00524	0.0256	CcSEcCtD
Sunitinib—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00475	0.0232	CcSEcCtD
Sunitinib—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00448	0.0218	CcSEcCtD
Sunitinib—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00448	0.0218	CcSEcCtD
Sunitinib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00436	0.0212	CcSEcCtD
Sunitinib—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00393	0.0191	CcSEcCtD
Sunitinib—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00388	0.0189	CcSEcCtD
Sunitinib—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00375	0.0183	CcSEcCtD
Sunitinib—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00351	0.0171	CcSEcCtD
Sunitinib—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00347	0.0169	CcSEcCtD
Sunitinib—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00324	0.0158	CcSEcCtD
Sunitinib—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00321	0.0156	CcSEcCtD
Sunitinib—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00321	0.0156	CcSEcCtD
Sunitinib—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00315	0.0154	CcSEcCtD
Sunitinib—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00312	0.0152	CcSEcCtD
Sunitinib—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00301	0.0147	CcSEcCtD
Sunitinib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0142	CcSEcCtD
Sunitinib—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00282	0.0137	CcSEcCtD
Sunitinib—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00277	0.0135	CcSEcCtD
Sunitinib—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00275	0.0134	CcSEcCtD
Sunitinib—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00269	0.0131	CcSEcCtD
Sunitinib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00245	0.0119	CcSEcCtD
Sunitinib—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00242	0.0118	CcSEcCtD
Sunitinib—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0115	CcSEcCtD
Sunitinib—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00227	0.0111	CcSEcCtD
Sunitinib—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0109	CcSEcCtD
Sunitinib—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0109	CcSEcCtD
Sunitinib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0106	CcSEcCtD
Sunitinib—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00215	0.0105	CcSEcCtD
Sunitinib—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00213	0.0104	CcSEcCtD
Sunitinib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00982	CcSEcCtD
Sunitinib—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00967	CcSEcCtD
Sunitinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00943	CcSEcCtD
Sunitinib—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00907	CcSEcCtD
Sunitinib—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00902	CcSEcCtD
Sunitinib—Eczema—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00878	CcSEcCtD
Sunitinib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00178	0.0087	CcSEcCtD
Sunitinib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00808	CcSEcCtD
Sunitinib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00792	CcSEcCtD
Sunitinib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00761	CcSEcCtD
Sunitinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00733	CcSEcCtD
Sunitinib—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00728	CcSEcCtD
Sunitinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00718	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0071	CcSEcCtD
Sunitinib—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00696	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00696	CcSEcCtD
Sunitinib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00686	CcSEcCtD
Sunitinib—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00682	CcSEcCtD
Sunitinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00668	CcSEcCtD
Sunitinib—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00656	CcSEcCtD
Sunitinib—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00653	CcSEcCtD
Sunitinib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00647	CcSEcCtD
Sunitinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00637	CcSEcCtD
Sunitinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00617	CcSEcCtD
Sunitinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00611	CcSEcCtD
Sunitinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00608	CcSEcCtD
Sunitinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00608	CcSEcCtD
Sunitinib—Depression—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00606	CcSEcCtD
Sunitinib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00599	CcSEcCtD
Sunitinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00596	CcSEcCtD
Sunitinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00592	CcSEcCtD
Sunitinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00591	CcSEcCtD
Sunitinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00575	CcSEcCtD
Sunitinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00573	CcSEcCtD
Sunitinib—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00555	CcSEcCtD
Sunitinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00548	CcSEcCtD
Sunitinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00546	CcSEcCtD
Sunitinib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00546	CcSEcCtD
Sunitinib—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00543	CcSEcCtD
Sunitinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00539	CcSEcCtD
Sunitinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00537	CcSEcCtD
Sunitinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00536	CcSEcCtD
Sunitinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00535	CcSEcCtD
Sunitinib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00516	CcSEcCtD
Sunitinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0051	CcSEcCtD
Sunitinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00506	CcSEcCtD
Sunitinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00495	CcSEcCtD
Sunitinib—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00493	CcSEcCtD
Sunitinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00492	CcSEcCtD
Sunitinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.001	0.0049	CcSEcCtD
Sunitinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.001	0.00487	CcSEcCtD
Sunitinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000989	0.00482	CcSEcCtD
Sunitinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000981	0.00478	CcSEcCtD
Sunitinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00475	CcSEcCtD
Sunitinib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00096	0.00468	CcSEcCtD
Sunitinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000954	0.00465	CcSEcCtD
Sunitinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000943	0.00459	CcSEcCtD
Sunitinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000937	0.00457	CcSEcCtD
Sunitinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000901	0.00439	CcSEcCtD
Sunitinib—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00089	0.00434	CcSEcCtD
Sunitinib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000872	0.00425	CcSEcCtD
Sunitinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.00085	0.00414	CcSEcCtD
Sunitinib—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000844	0.00412	CcSEcCtD
Sunitinib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000841	0.0041	CcSEcCtD
Sunitinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00083	0.00404	CcSEcCtD
Sunitinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00083	0.00404	CcSEcCtD
Sunitinib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00083	0.00404	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000824	0.00402	CcSEcCtD
Sunitinib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000811	0.00395	CcSEcCtD
Sunitinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000795	0.00388	CcSEcCtD
Sunitinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00385	CcSEcCtD
Sunitinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000782	0.00381	CcSEcCtD
Sunitinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00078	0.0038	CcSEcCtD
Sunitinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000779	0.0038	CcSEcCtD
Sunitinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000772	0.00377	CcSEcCtD
Sunitinib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000758	0.00369	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000725	0.00353	CcSEcCtD
Sunitinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000719	0.00351	CcSEcCtD
Sunitinib—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000714	0.00348	CcSEcCtD
Sunitinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00346	CcSEcCtD
Sunitinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00341	CcSEcCtD
Sunitinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000691	0.00337	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000687	0.00335	CcSEcCtD
Sunitinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00334	CcSEcCtD
Sunitinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00331	CcSEcCtD
Sunitinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00331	CcSEcCtD
Sunitinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00065	0.00317	CcSEcCtD
Sunitinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000629	0.00306	CcSEcCtD
Sunitinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000629	0.00306	CcSEcCtD
Sunitinib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000586	0.00286	CcSEcCtD
Sunitinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000571	0.00278	CcSEcCtD
Sunitinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000563	0.00274	CcSEcCtD
Sunitinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000544	0.00265	CcSEcCtD
Sunitinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000526	0.00256	CcSEcCtD
Sunitinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000506	0.00246	CcSEcCtD
Sunitinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000501	0.00244	CcSEcCtD
Sunitinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000501	0.00244	CcSEcCtD
Sunitinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000498	0.00243	CcSEcCtD
Sunitinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000472	0.0023	CcSEcCtD
Sunitinib—DYRK1A—central nervous system—amyotrophic lateral sclerosis	0.000353	0.00136	CbGeAlD
Sunitinib—MAP4K4—nervous system—amyotrophic lateral sclerosis	0.000351	0.00135	CbGeAlD
Sunitinib—KIT—brainstem—amyotrophic lateral sclerosis	0.00035	0.00135	CbGeAlD
Sunitinib—JAK2—medulla oblongata—amyotrophic lateral sclerosis	0.000349	0.00135	CbGeAlD
Sunitinib—PRPF4B—brain—amyotrophic lateral sclerosis	0.000349	0.00135	CbGeAlD
Sunitinib—MAP3K7—spinal cord—amyotrophic lateral sclerosis	0.000349	0.00134	CbGeAlD
Sunitinib—MAP3K12—nervous system—amyotrophic lateral sclerosis	0.000346	0.00134	CbGeAlD
Sunitinib—DYRK1A—cerebellum—amyotrophic lateral sclerosis	0.000345	0.00133	CbGeAlD
Sunitinib—TBK1—spinal cord—amyotrophic lateral sclerosis	0.000345	0.00133	CbGeAlD
Sunitinib—MERTK—central nervous system—amyotrophic lateral sclerosis	0.000345	0.00133	CbGeAlD
Sunitinib—FYN—medulla oblongata—amyotrophic lateral sclerosis	0.000345	0.00133	CbGeAlD
Sunitinib—STK39—brain—amyotrophic lateral sclerosis	0.000345	0.00133	CbGeAlD
Sunitinib—TYK2—spinal cord—amyotrophic lateral sclerosis	0.000343	0.00132	CbGeAlD
Sunitinib—RPS6KA3—nervous system—amyotrophic lateral sclerosis	0.000342	0.00132	CbGeAlD
Sunitinib—CSNK2A1—brain—amyotrophic lateral sclerosis	0.00034	0.00131	CbGeAlD
Sunitinib—MAP2K1—nervous system—amyotrophic lateral sclerosis	0.000339	0.00131	CbGeAlD
Sunitinib—MAP4K4—central nervous system—amyotrophic lateral sclerosis	0.000338	0.0013	CbGeAlD
Sunitinib—MERTK—cerebellum—amyotrophic lateral sclerosis	0.000337	0.0013	CbGeAlD
Sunitinib—MAP4K5—medulla oblongata—amyotrophic lateral sclerosis	0.000337	0.0013	CbGeAlD
Sunitinib—MAP3K3—medulla oblongata—amyotrophic lateral sclerosis	0.000337	0.0013	CbGeAlD
Sunitinib—MYLK—brain—amyotrophic lateral sclerosis	0.000336	0.00129	CbGeAlD
Sunitinib—CSNK1A1—nervous system—amyotrophic lateral sclerosis	0.000335	0.00129	CbGeAlD
Sunitinib—MAP3K12—central nervous system—amyotrophic lateral sclerosis	0.000334	0.00129	CbGeAlD
Sunitinib—CLK1—nervous system—amyotrophic lateral sclerosis	0.000333	0.00128	CbGeAlD
Sunitinib—RPS6KB1—spinal cord—amyotrophic lateral sclerosis	0.000332	0.00128	CbGeAlD
Sunitinib—PLK4—brain—amyotrophic lateral sclerosis	0.000332	0.00128	CbGeAlD
Sunitinib—MAP4K4—cerebellum—amyotrophic lateral sclerosis	0.000331	0.00127	CbGeAlD
Sunitinib—RET—spinal cord—amyotrophic lateral sclerosis	0.00033	0.00127	CbGeAlD
Sunitinib—STK4—brain—amyotrophic lateral sclerosis	0.00033	0.00127	CbGeAlD
Sunitinib—RPS6KA3—central nervous system—amyotrophic lateral sclerosis	0.000329	0.00127	CbGeAlD
Sunitinib—AXL—spinal cord—amyotrophic lateral sclerosis	0.000328	0.00127	CbGeAlD
Sunitinib—NUAK2—cerebellum—amyotrophic lateral sclerosis	0.000328	0.00127	CbGeAlD
Sunitinib—MAP2K1—central nervous system—amyotrophic lateral sclerosis	0.000327	0.00126	CbGeAlD
Sunitinib—CAMK2G—nervous system—amyotrophic lateral sclerosis	0.000327	0.00126	CbGeAlD
Sunitinib—BMP2K—nervous system—amyotrophic lateral sclerosis	0.000327	0.00126	CbGeAlD
Sunitinib—MAP3K12—cerebellum—amyotrophic lateral sclerosis	0.000326	0.00126	CbGeAlD
Sunitinib—FLT3—cerebellum—amyotrophic lateral sclerosis	0.000326	0.00126	CbGeAlD
Sunitinib—FLT1—medulla oblongata—amyotrophic lateral sclerosis	0.000326	0.00126	CbGeAlD
Sunitinib—LRRK2—nervous system—amyotrophic lateral sclerosis	0.000324	0.00125	CbGeAlD
Sunitinib—PHKG2—brain—amyotrophic lateral sclerosis	0.000324	0.00125	CbGeAlD
Sunitinib—CSNK1A1—central nervous system—amyotrophic lateral sclerosis	0.000323	0.00124	CbGeAlD
Sunitinib—EPHB6—medulla oblongata—amyotrophic lateral sclerosis	0.000322	0.00124	CbGeAlD
Sunitinib—STK24—brain—amyotrophic lateral sclerosis	0.000322	0.00124	CbGeAlD
Sunitinib—RPS6KA3—cerebellum—amyotrophic lateral sclerosis	0.000322	0.00124	CbGeAlD
Sunitinib—CLK1—central nervous system—amyotrophic lateral sclerosis	0.00032	0.00124	CbGeAlD
Sunitinib—MAP2K1—cerebellum—amyotrophic lateral sclerosis	0.000319	0.00123	CbGeAlD
Sunitinib—PRKAA1—nervous system—amyotrophic lateral sclerosis	0.000319	0.00123	CbGeAlD
Sunitinib—DAPK2—brain—amyotrophic lateral sclerosis	0.000318	0.00123	CbGeAlD
Sunitinib—SLK—spinal cord—amyotrophic lateral sclerosis	0.000316	0.00122	CbGeAlD
Sunitinib—PTK2B—nervous system—amyotrophic lateral sclerosis	0.000316	0.00122	CbGeAlD
Sunitinib—CSNK1A1—cerebellum—amyotrophic lateral sclerosis	0.000315	0.00122	CbGeAlD
Sunitinib—CAMK2G—central nervous system—amyotrophic lateral sclerosis	0.000315	0.00121	CbGeAlD
Sunitinib—BMP2K—central nervous system—amyotrophic lateral sclerosis	0.000315	0.00121	CbGeAlD
Sunitinib—FGFR2—spinal cord—amyotrophic lateral sclerosis	0.000313	0.00121	CbGeAlD
Sunitinib—CLK1—cerebellum—amyotrophic lateral sclerosis	0.000313	0.00121	CbGeAlD
Sunitinib—STK16—brain—amyotrophic lateral sclerosis	0.000313	0.00121	CbGeAlD
Sunitinib—LRRK2—central nervous system—amyotrophic lateral sclerosis	0.000312	0.0012	CbGeAlD
Sunitinib—JAK2—spinal cord—amyotrophic lateral sclerosis	0.000312	0.0012	CbGeAlD
Sunitinib—HIPK2—brain—amyotrophic lateral sclerosis	0.000311	0.0012	CbGeAlD
Sunitinib—HIPK3—brain—amyotrophic lateral sclerosis	0.000311	0.0012	CbGeAlD
Sunitinib—ALK—brain—amyotrophic lateral sclerosis	0.000311	0.0012	CbGeAlD
Sunitinib—TYRO3—brain—amyotrophic lateral sclerosis	0.000311	0.0012	CbGeAlD
Sunitinib—YES1—medulla oblongata—amyotrophic lateral sclerosis	0.000311	0.0012	CbGeAlD
Sunitinib—CSNK1E—nervous system—amyotrophic lateral sclerosis	0.00031	0.0012	CbGeAlD
Sunitinib—TNK1—brain—amyotrophic lateral sclerosis	0.000308	0.00119	CbGeAlD
Sunitinib—RIOK2—brain—amyotrophic lateral sclerosis	0.000308	0.00119	CbGeAlD
Sunitinib—BMP2K—cerebellum—amyotrophic lateral sclerosis	0.000307	0.00119	CbGeAlD
Sunitinib—CAMK2G—cerebellum—amyotrophic lateral sclerosis	0.000307	0.00119	CbGeAlD
Sunitinib—FYN—spinal cord—amyotrophic lateral sclerosis	0.000307	0.00118	CbGeAlD
Sunitinib—PRKAA1—central nervous system—amyotrophic lateral sclerosis	0.000307	0.00118	CbGeAlD
Sunitinib—TAOK3—medulla oblongata—amyotrophic lateral sclerosis	0.000307	0.00118	CbGeAlD
Sunitinib—IRAK4—nervous system—amyotrophic lateral sclerosis	0.000306	0.00118	CbGeAlD
Sunitinib—MAP4K1—brain—amyotrophic lateral sclerosis	0.000305	0.00118	CbGeAlD
Sunitinib—MAP3K19—brain—amyotrophic lateral sclerosis	0.000305	0.00118	CbGeAlD
Sunitinib—LRRK2—cerebellum—amyotrophic lateral sclerosis	0.000305	0.00117	CbGeAlD
Sunitinib—PTK2B—central nervous system—amyotrophic lateral sclerosis	0.000304	0.00117	CbGeAlD
Sunitinib—MAP3K3—spinal cord—amyotrophic lateral sclerosis	0.0003	0.00116	CbGeAlD
Sunitinib—MAP4K5—spinal cord—amyotrophic lateral sclerosis	0.0003	0.00116	CbGeAlD
Sunitinib—PRKAA1—cerebellum—amyotrophic lateral sclerosis	0.0003	0.00116	CbGeAlD
Sunitinib—DAPK3—brain—amyotrophic lateral sclerosis	0.000299	0.00115	CbGeAlD
Sunitinib—CSNK1E—central nervous system—amyotrophic lateral sclerosis	0.000299	0.00115	CbGeAlD
Sunitinib—MAP2K2—nervous system—amyotrophic lateral sclerosis	0.000299	0.00115	CbGeAlD
Sunitinib—ULK3—nervous system—amyotrophic lateral sclerosis	0.000299	0.00115	CbGeAlD
Sunitinib—PTK2B—cerebellum—amyotrophic lateral sclerosis	0.000297	0.00114	CbGeAlD
Sunitinib—MAP3K2—nervous system—amyotrophic lateral sclerosis	0.000297	0.00114	CbGeAlD
Sunitinib—CLK2—brain—amyotrophic lateral sclerosis	0.000296	0.00114	CbGeAlD
Sunitinib—MAP4K2—brain—amyotrophic lateral sclerosis	0.000295	0.00114	CbGeAlD
Sunitinib—IRAK4—central nervous system—amyotrophic lateral sclerosis	0.000294	0.00113	CbGeAlD
Sunitinib—CSNK1E—cerebellum—amyotrophic lateral sclerosis	0.000292	0.00113	CbGeAlD
Sunitinib—FGFR1—cerebellum—amyotrophic lateral sclerosis	0.000292	0.00113	CbGeAlD
Sunitinib—STK3—brain—amyotrophic lateral sclerosis	0.000291	0.00112	CbGeAlD
Sunitinib—TBK1—nervous system—amyotrophic lateral sclerosis	0.000291	0.00112	CbGeAlD
Sunitinib—FLT1—spinal cord—amyotrophic lateral sclerosis	0.00029	0.00112	CbGeAlD
Sunitinib—TYK2—nervous system—amyotrophic lateral sclerosis	0.000289	0.00111	CbGeAlD
Sunitinib—MAP2K2—central nervous system—amyotrophic lateral sclerosis	0.000288	0.00111	CbGeAlD
Sunitinib—ULK3—central nervous system—amyotrophic lateral sclerosis	0.000288	0.00111	CbGeAlD
Sunitinib—IRAK4—cerebellum—amyotrophic lateral sclerosis	0.000288	0.00111	CbGeAlD
Sunitinib—ROCK1—brain—amyotrophic lateral sclerosis	0.000287	0.00111	CbGeAlD
Sunitinib—EPHB6—spinal cord—amyotrophic lateral sclerosis	0.000287	0.00111	CbGeAlD
Sunitinib—MAP3K2—central nervous system—amyotrophic lateral sclerosis	0.000286	0.0011	CbGeAlD
Sunitinib—ULK3—cerebellum—amyotrophic lateral sclerosis	0.000281	0.00108	CbGeAlD
Sunitinib—MAP2K2—cerebellum—amyotrophic lateral sclerosis	0.000281	0.00108	CbGeAlD
Sunitinib—DYRK1A—brain—amyotrophic lateral sclerosis	0.00028	0.00108	CbGeAlD
Sunitinib—TBK1—central nervous system—amyotrophic lateral sclerosis	0.00028	0.00108	CbGeAlD
Sunitinib—RPS6KB1—nervous system—amyotrophic lateral sclerosis	0.00028	0.00108	CbGeAlD
Sunitinib—MAP3K2—cerebellum—amyotrophic lateral sclerosis	0.000279	0.00108	CbGeAlD
Sunitinib—TYK2—central nervous system—amyotrophic lateral sclerosis	0.000278	0.00107	CbGeAlD
Sunitinib—FGR—nervous system—amyotrophic lateral sclerosis	0.000278	0.00107	CbGeAlD
Sunitinib—RET—nervous system—amyotrophic lateral sclerosis	0.000278	0.00107	CbGeAlD
Sunitinib—YES1—spinal cord—amyotrophic lateral sclerosis	0.000277	0.00107	CbGeAlD
Sunitinib—AXL—nervous system—amyotrophic lateral sclerosis	0.000277	0.00107	CbGeAlD
Sunitinib—MAP3K7—cerebellum—amyotrophic lateral sclerosis	0.000277	0.00107	CbGeAlD
Sunitinib—KDR—medulla oblongata—amyotrophic lateral sclerosis	0.000275	0.00106	CbGeAlD
Sunitinib—MAP2K5—medulla oblongata—amyotrophic lateral sclerosis	0.000275	0.00106	CbGeAlD
Sunitinib—TAOK3—spinal cord—amyotrophic lateral sclerosis	0.000274	0.00106	CbGeAlD
Sunitinib—MERTK—brain—amyotrophic lateral sclerosis	0.000274	0.00106	CbGeAlD
Sunitinib—TBK1—cerebellum—amyotrophic lateral sclerosis	0.000273	0.00105	CbGeAlD
Sunitinib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.000272	0.00105	CbGeAlD
Sunitinib—TYK2—cerebellum—amyotrophic lateral sclerosis	0.000272	0.00105	CbGeAlD
Sunitinib—RPS6KB1—central nervous system—amyotrophic lateral sclerosis	0.000269	0.00104	CbGeAlD
Sunitinib—CSF1R—medulla oblongata—amyotrophic lateral sclerosis	0.000269	0.00104	CbGeAlD
Sunitinib—MAP4K4—brain—amyotrophic lateral sclerosis	0.000269	0.00104	CbGeAlD
Sunitinib—IRAK1—cerebellum—amyotrophic lateral sclerosis	0.000268	0.00103	CbGeAlD
Sunitinib—RET—central nervous system—amyotrophic lateral sclerosis	0.000267	0.00103	CbGeAlD
Sunitinib—FGR—central nervous system—amyotrophic lateral sclerosis	0.000267	0.00103	CbGeAlD
Sunitinib—NUAK2—brain—amyotrophic lateral sclerosis	0.000267	0.00103	CbGeAlD
Sunitinib—AXL—central nervous system—amyotrophic lateral sclerosis	0.000266	0.00103	CbGeAlD
Sunitinib—MAP3K12—brain—amyotrophic lateral sclerosis	0.000265	0.00102	CbGeAlD
Sunitinib—FGFR2—nervous system—amyotrophic lateral sclerosis	0.000264	0.00102	CbGeAlD
Sunitinib—RPS6KB1—cerebellum—amyotrophic lateral sclerosis	0.000263	0.00101	CbGeAlD
Sunitinib—JAK2—nervous system—amyotrophic lateral sclerosis	0.000263	0.00101	CbGeAlD
Sunitinib—RET—cerebellum—amyotrophic lateral sclerosis	0.000261	0.00101	CbGeAlD
Sunitinib—RPS6KA3—brain—amyotrophic lateral sclerosis	0.000261	0.00101	CbGeAlD
Sunitinib—AXL—cerebellum—amyotrophic lateral sclerosis	0.00026	0.001	CbGeAlD
Sunitinib—MAP2K1—brain—amyotrophic lateral sclerosis	0.000259	0.001	CbGeAlD
Sunitinib—FYN—nervous system—amyotrophic lateral sclerosis	0.000259	0.000998	CbGeAlD
Sunitinib—CSNK1A1—brain—amyotrophic lateral sclerosis	0.000256	0.000987	CbGeAlD
Sunitinib—CLK1—brain—amyotrophic lateral sclerosis	0.000254	0.000981	CbGeAlD
Sunitinib—FGFR2—central nervous system—amyotrophic lateral sclerosis	0.000254	0.00098	CbGeAlD
Sunitinib—MAP4K5—nervous system—amyotrophic lateral sclerosis	0.000253	0.000976	CbGeAlD
Sunitinib—MAP3K3—nervous system—amyotrophic lateral sclerosis	0.000253	0.000976	CbGeAlD
Sunitinib—JAK2—central nervous system—amyotrophic lateral sclerosis	0.000253	0.000975	CbGeAlD
Sunitinib—SLK—cerebellum—amyotrophic lateral sclerosis	0.000251	0.000966	CbGeAlD
Sunitinib—CAMK2G—brain—amyotrophic lateral sclerosis	0.00025	0.000963	CbGeAlD
Sunitinib—BMP2K—brain—amyotrophic lateral sclerosis	0.00025	0.000963	CbGeAlD
Sunitinib—FYN—central nervous system—amyotrophic lateral sclerosis	0.000249	0.000961	CbGeAlD
Sunitinib—FGFR2—cerebellum—amyotrophic lateral sclerosis	0.000248	0.000958	CbGeAlD
Sunitinib—LRRK2—brain—amyotrophic lateral sclerosis	0.000248	0.000954	CbGeAlD
Sunitinib—JAK2—cerebellum—amyotrophic lateral sclerosis	0.000247	0.000953	CbGeAlD
Sunitinib—KDR—spinal cord—amyotrophic lateral sclerosis	0.000245	0.000946	CbGeAlD
Sunitinib—MAP2K5—spinal cord—amyotrophic lateral sclerosis	0.000245	0.000946	CbGeAlD
Sunitinib—FLT1—nervous system—amyotrophic lateral sclerosis	0.000245	0.000943	CbGeAlD
Sunitinib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.000244	0.00094	CbGeAlD
Sunitinib—PRKAA1—brain—amyotrophic lateral sclerosis	0.000244	0.00094	CbGeAlD
Sunitinib—FYN—cerebellum—amyotrophic lateral sclerosis	0.000244	0.000939	CbGeAlD
Sunitinib—MAP4K5—central nervous system—amyotrophic lateral sclerosis	0.000244	0.000939	CbGeAlD
Sunitinib—MAP3K3—central nervous system—amyotrophic lateral sclerosis	0.000244	0.000939	CbGeAlD
Sunitinib—EPHB6—nervous system—amyotrophic lateral sclerosis	0.000242	0.000932	CbGeAlD
Sunitinib—PTK2B—brain—amyotrophic lateral sclerosis	0.000241	0.00093	CbGeAlD
Sunitinib—FLT4—brain—amyotrophic lateral sclerosis	0.000241	0.000927	CbGeAlD
Sunitinib—CSF1R—spinal cord—amyotrophic lateral sclerosis	0.00024	0.000924	CbGeAlD
Sunitinib—PDGFRB—medulla oblongata—amyotrophic lateral sclerosis	0.000238	0.000919	CbGeAlD
Sunitinib—MAP4K5—cerebellum—amyotrophic lateral sclerosis	0.000238	0.000918	CbGeAlD
Sunitinib—MAP3K3—cerebellum—amyotrophic lateral sclerosis	0.000238	0.000918	CbGeAlD
Sunitinib—CSNK1E—brain—amyotrophic lateral sclerosis	0.000237	0.000915	CbGeAlD
Sunitinib—FGFR1—brain—amyotrophic lateral sclerosis	0.000237	0.000915	CbGeAlD
Sunitinib—FLT1—central nervous system—amyotrophic lateral sclerosis	0.000236	0.000908	CbGeAlD
Sunitinib—YES1—nervous system—amyotrophic lateral sclerosis	0.000234	0.000901	CbGeAlD
Sunitinib—IRAK4—brain—amyotrophic lateral sclerosis	0.000234	0.000901	CbGeAlD
Sunitinib—EPHB6—central nervous system—amyotrophic lateral sclerosis	0.000233	0.000898	CbGeAlD
Sunitinib—STK10—nervous system—amyotrophic lateral sclerosis	0.000232	0.000893	CbGeAlD
Sunitinib—TAOK3—nervous system—amyotrophic lateral sclerosis	0.000231	0.000889	CbGeAlD
Sunitinib—FLT1—cerebellum—amyotrophic lateral sclerosis	0.00023	0.000888	CbGeAlD
Sunitinib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.000229	0.000884	CbGeAlD
Sunitinib—MAP2K2—brain—amyotrophic lateral sclerosis	0.000228	0.000881	CbGeAlD
Sunitinib—ULK3—brain—amyotrophic lateral sclerosis	0.000228	0.000881	CbGeAlD
Sunitinib—EPHB6—cerebellum—amyotrophic lateral sclerosis	0.000228	0.000877	CbGeAlD
Sunitinib—MAP3K2—brain—amyotrophic lateral sclerosis	0.000227	0.000874	CbGeAlD
Sunitinib—YES1—central nervous system—amyotrophic lateral sclerosis	0.000225	0.000867	CbGeAlD
Sunitinib—MAP3K7—brain—amyotrophic lateral sclerosis	0.000225	0.000866	CbGeAlD
Sunitinib—STK10—central nervous system—amyotrophic lateral sclerosis	0.000223	0.00086	CbGeAlD
Sunitinib—TAOK3—central nervous system—amyotrophic lateral sclerosis	0.000222	0.000856	CbGeAlD
Sunitinib—TBK1—brain—amyotrophic lateral sclerosis	0.000222	0.000856	CbGeAlD
Sunitinib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000221	0.000851	CbGeAlD
Sunitinib—TYK2—brain—amyotrophic lateral sclerosis	0.000221	0.00085	CbGeAlD
Sunitinib—YES1—cerebellum—amyotrophic lateral sclerosis	0.00022	0.000848	CbGeAlD
Sunitinib—STK10—cerebellum—amyotrophic lateral sclerosis	0.000218	0.00084	CbGeAlD
Sunitinib—IRAK1—brain—amyotrophic lateral sclerosis	0.000218	0.000839	CbGeAlD
Sunitinib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000218	0.000839	CbGeAlD
Sunitinib—TAOK3—cerebellum—amyotrophic lateral sclerosis	0.000217	0.000837	CbGeAlD
Sunitinib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.000216	0.000832	CbGeAlD
Sunitinib—RPS6KB1—brain—amyotrophic lateral sclerosis	0.000214	0.000824	CbGeAlD
Sunitinib—PDGFRB—spinal cord—amyotrophic lateral sclerosis	0.000212	0.000819	CbGeAlD
Sunitinib—FGR—brain—amyotrophic lateral sclerosis	0.000212	0.000819	CbGeAlD
Sunitinib—RET—brain—amyotrophic lateral sclerosis	0.000212	0.000819	CbGeAlD
Sunitinib—AXL—brain—amyotrophic lateral sclerosis	0.000211	0.000815	CbGeAlD
Sunitinib—MAP2K5—nervous system—amyotrophic lateral sclerosis	0.000207	0.000797	CbGeAlD
Sunitinib—KDR—nervous system—amyotrophic lateral sclerosis	0.000207	0.000797	CbGeAlD
Sunitinib—SLK—brain—amyotrophic lateral sclerosis	0.000204	0.000785	CbGeAlD
Sunitinib—CSF1R—nervous system—amyotrophic lateral sclerosis	0.000202	0.000778	CbGeAlD
Sunitinib—FGFR2—brain—amyotrophic lateral sclerosis	0.000202	0.000778	CbGeAlD
Sunitinib—JAK2—brain—amyotrophic lateral sclerosis	0.000201	0.000774	CbGeAlD
Sunitinib—KDR—central nervous system—amyotrophic lateral sclerosis	0.000199	0.000768	CbGeAlD
Sunitinib—MAP2K5—central nervous system—amyotrophic lateral sclerosis	0.000199	0.000768	CbGeAlD
Sunitinib—FYN—brain—amyotrophic lateral sclerosis	0.000198	0.000763	CbGeAlD
Sunitinib—KDR—cerebellum—amyotrophic lateral sclerosis	0.000195	0.00075	CbGeAlD
Sunitinib—MAP2K5—cerebellum—amyotrophic lateral sclerosis	0.000195	0.00075	CbGeAlD
Sunitinib—CSF1R—central nervous system—amyotrophic lateral sclerosis	0.000194	0.000749	CbGeAlD
Sunitinib—MAP4K5—brain—amyotrophic lateral sclerosis	0.000193	0.000746	CbGeAlD
Sunitinib—MAP3K3—brain—amyotrophic lateral sclerosis	0.000193	0.000746	CbGeAlD
Sunitinib—CSF1R—cerebellum—amyotrophic lateral sclerosis	0.00019	0.000732	CbGeAlD
Sunitinib—FLT1—brain—amyotrophic lateral sclerosis	0.000187	0.000721	CbGeAlD
Sunitinib—EPHB6—brain—amyotrophic lateral sclerosis	0.000185	0.000713	CbGeAlD
Sunitinib—KIT—nervous system—amyotrophic lateral sclerosis	0.000183	0.000707	CbGeAlD
Sunitinib—PDGFRB—nervous system—amyotrophic lateral sclerosis	0.000179	0.00069	CbGeAlD
Sunitinib—YES1—brain—amyotrophic lateral sclerosis	0.000179	0.000689	CbGeAlD
Sunitinib—STK10—brain—amyotrophic lateral sclerosis	0.000177	0.000682	CbGeAlD
Sunitinib—KIT—central nervous system—amyotrophic lateral sclerosis	0.000176	0.00068	CbGeAlD
Sunitinib—TAOK3—brain—amyotrophic lateral sclerosis	0.000176	0.00068	CbGeAlD
Sunitinib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000175	0.000676	CbGeAlD
Sunitinib—KIT—cerebellum—amyotrophic lateral sclerosis	0.000172	0.000665	CbGeAlD
Sunitinib—PDGFRB—central nervous system—amyotrophic lateral sclerosis	0.000172	0.000664	CbGeAlD
Sunitinib—PDGFRB—cerebellum—amyotrophic lateral sclerosis	0.000168	0.000649	CbGeAlD
Sunitinib—KDR—brain—amyotrophic lateral sclerosis	0.000158	0.000609	CbGeAlD
Sunitinib—MAP2K5—brain—amyotrophic lateral sclerosis	0.000158	0.000609	CbGeAlD
Sunitinib—CSF1R—brain—amyotrophic lateral sclerosis	0.000154	0.000595	CbGeAlD
Sunitinib—KCNH2—medulla oblongata—amyotrophic lateral sclerosis	0.000151	0.00058	CbGeAlD
Sunitinib—ABCC4—nervous system—amyotrophic lateral sclerosis	0.000143	0.00055	CbGeAlD
Sunitinib—KIT—brain—amyotrophic lateral sclerosis	0.00014	0.00054	CbGeAlD
Sunitinib—ABCC4—central nervous system—amyotrophic lateral sclerosis	0.000137	0.000529	CbGeAlD
Sunitinib—PDGFRB—brain—amyotrophic lateral sclerosis	0.000137	0.000528	CbGeAlD
Sunitinib—KCNH2—spinal cord—amyotrophic lateral sclerosis	0.000134	0.000517	CbGeAlD
Sunitinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000134	0.000516	CbGeAlD
Sunitinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000119	0.00046	CbGeAlD
Sunitinib—KCNH2—nervous system—amyotrophic lateral sclerosis	0.000113	0.000436	CbGeAlD
Sunitinib—ABCC4—brain—amyotrophic lateral sclerosis	0.000109	0.00042	CbGeAlD
Sunitinib—KCNH2—central nervous system—amyotrophic lateral sclerosis	0.000109	0.00042	CbGeAlD
Sunitinib—KCNH2—cerebellum—amyotrophic lateral sclerosis	0.000106	0.00041	CbGeAlD
Sunitinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000103	0.000398	CbGeAlD
Sunitinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	9.47e-05	0.000365	CbGeAlD
Sunitinib—KCNH2—brain—amyotrophic lateral sclerosis	8.65e-05	0.000333	CbGeAlD
Sunitinib—ABCG2—brain—amyotrophic lateral sclerosis	7.69e-05	0.000296	CbGeAlD
Sunitinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	7.01e-05	0.00027	CbGeAlD
Sunitinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	6.75e-05	0.00026	CbGeAlD
Sunitinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	6.6e-05	0.000255	CbGeAlD
Sunitinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	5.89e-05	0.000227	CbGeAlD
Sunitinib—ABCB1—nervous system—amyotrophic lateral sclerosis	4.96e-05	0.000191	CbGeAlD
Sunitinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	4.78e-05	0.000184	CbGeAlD
Sunitinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	4.67e-05	0.00018	CbGeAlD
Sunitinib—ABCB1—brain—amyotrophic lateral sclerosis	3.79e-05	0.000146	CbGeAlD
Sunitinib—FYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.63e-06	1.59e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.63e-06	1.59e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.62e-06	1.59e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.6e-06	1.59e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.59e-06	1.58e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.59e-06	1.58e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.58e-06	1.58e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.58e-06	1.58e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.57e-06	1.58e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.57e-06	1.58e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.56e-06	1.57e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	5.53e-06	1.56e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.52e-06	1.56e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.51e-06	1.56e-05	CbGpPWpGaD
Sunitinib—JAK2—Immune System—C3—amyotrophic lateral sclerosis	5.48e-06	1.55e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.48e-06	1.55e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.48e-06	1.55e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.46e-06	1.55e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.46e-06	1.55e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.45e-06	1.54e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.45e-06	1.54e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.44e-06	1.54e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.43e-06	1.54e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	5.43e-06	1.54e-05	CbGpPWpGaD
Sunitinib—JAK2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.36e-06	1.52e-05	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.35e-06	1.51e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.3e-06	1.5e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.29e-06	1.5e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.28e-06	1.5e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—APOE—amyotrophic lateral sclerosis	5.27e-06	1.49e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.26e-06	1.49e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.25e-06	1.49e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	5.25e-06	1.49e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.25e-06	1.49e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.24e-06	1.48e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.23e-06	1.48e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.23e-06	1.48e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.22e-06	1.48e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.21e-06	1.47e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.18e-06	1.47e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.17e-06	1.46e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—APOE—amyotrophic lateral sclerosis	5.14e-06	1.46e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.13e-06	1.45e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.13e-06	1.45e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.08e-06	1.44e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.01e-06	1.42e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.98e-06	1.41e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.98e-06	1.41e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.96e-06	1.4e-05	CbGpPWpGaD
Sunitinib—FYN—Disease—APOE—amyotrophic lateral sclerosis	4.96e-06	1.4e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.96e-06	1.4e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—APOE—amyotrophic lateral sclerosis	4.93e-06	1.4e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.92e-06	1.39e-05	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.89e-06	1.38e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.87e-06	1.38e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.86e-06	1.38e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.82e-06	1.36e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.79e-06	1.36e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	4.78e-06	1.35e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.77e-06	1.35e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.76e-06	1.35e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.73e-06	1.34e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.72e-06	1.34e-05	CbGpPWpGaD
Sunitinib—JAK2—Disease—APOE—amyotrophic lateral sclerosis	4.71e-06	1.33e-05	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.71e-06	1.33e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.68e-06	1.32e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.66e-06	1.32e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.62e-06	1.31e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.62e-06	1.31e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.62e-06	1.31e-05	CbGpPWpGaD
Sunitinib—ABCC4—Hemostasis—TP53—amyotrophic lateral sclerosis	4.59e-06	1.3e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.54e-06	1.28e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.54e-06	1.28e-05	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.5e-06	1.27e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.5e-06	1.27e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.49e-06	1.27e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.49e-06	1.27e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.49e-06	1.27e-05	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.47e-06	1.27e-05	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.47e-06	1.27e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.46e-06	1.26e-05	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	4.46e-06	1.26e-05	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.45e-06	1.26e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.43e-06	1.25e-05	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.42e-06	1.25e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.39e-06	1.24e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.38e-06	1.24e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.35e-06	1.23e-05	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.34e-06	1.23e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.31e-06	1.22e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.3e-06	1.22e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.29e-06	1.22e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.27e-06	1.21e-05	CbGpPWpGaD
Sunitinib—TYK2—Disease—PTGS2—amyotrophic lateral sclerosis	4.26e-06	1.21e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.25e-06	1.2e-05	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.22e-06	1.2e-05	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.22e-06	1.2e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.22e-06	1.19e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.22e-06	1.19e-05	CbGpPWpGaD
Sunitinib—FGFR2—Disease—PTGS2—amyotrophic lateral sclerosis	4.21e-06	1.19e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.2e-06	1.19e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.18e-06	1.18e-05	CbGpPWpGaD
Sunitinib—FYN—Hemostasis—TP53—amyotrophic lateral sclerosis	4.18e-06	1.18e-05	CbGpPWpGaD
Sunitinib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	4.13e-06	1.17e-05	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.07e-06	1.15e-05	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.03e-06	1.14e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.01e-06	1.14e-05	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.01e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4e-06	1.13e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.99e-06	1.13e-05	CbGpPWpGaD
Sunitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.97e-06	1.12e-05	CbGpPWpGaD
Sunitinib—JAK2—Hemostasis—TP53—amyotrophic lateral sclerosis	3.97e-06	1.12e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.96e-06	1.12e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.95e-06	1.12e-05	CbGpPWpGaD
Sunitinib—FGFR1—Disease—PTGS2—amyotrophic lateral sclerosis	3.92e-06	1.11e-05	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	3.91e-06	1.11e-05	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.91e-06	1.11e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.87e-06	1.1e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.83e-06	1.08e-05	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.82e-06	1.08e-05	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.78e-06	1.07e-05	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.75e-06	1.06e-05	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.73e-06	1.06e-05	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.71e-06	1.05e-05	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.71e-06	1.05e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.69e-06	1.04e-05	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.69e-06	1.04e-05	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.67e-06	1.04e-05	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.62e-06	1.03e-05	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.62e-06	1.02e-05	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—PTGS2—amyotrophic lateral sclerosis	3.61e-06	1.02e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.6e-06	1.02e-05	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.6e-06	1.02e-05	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.58e-06	1.01e-05	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.57e-06	1.01e-05	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.56e-06	1.01e-05	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.56e-06	1.01e-05	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.55e-06	1.01e-05	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.55e-06	1e-05	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.54e-06	1e-05	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—PTGS2—amyotrophic lateral sclerosis	3.52e-06	9.98e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.49e-06	9.88e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.49e-06	9.88e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.49e-06	9.87e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.47e-06	9.83e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.46e-06	9.81e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.46e-06	9.81e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.45e-06	9.77e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PTGS2—amyotrophic lateral sclerosis	3.4e-06	9.62e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PTGS2—amyotrophic lateral sclerosis	3.38e-06	9.56e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.36e-06	9.52e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.36e-06	9.51e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.36e-06	9.51e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	3.35e-06	9.48e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.34e-06	9.46e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.34e-06	9.45e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	3.32e-06	9.4e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.31e-06	9.38e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.3e-06	9.35e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.3e-06	9.34e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.27e-06	9.27e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.25e-06	9.2e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PTGS2—amyotrophic lateral sclerosis	3.23e-06	9.14e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.17e-06	8.98e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.13e-06	8.86e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.11e-06	8.81e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.05e-06	8.63e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.02e-06	8.54e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.02e-06	8.54e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.01e-06	8.51e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.98e-06	8.42e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.94e-06	8.32e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.92e-06	8.25e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.88e-06	8.16e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.87e-06	8.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.85e-06	8.08e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.85e-06	8.08e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.84e-06	8.05e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.77e-06	7.84e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.75e-06	7.77e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.74e-06	7.74e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.73e-06	7.72e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.71e-06	7.66e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.7e-06	7.63e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.69e-06	7.6e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.69e-06	7.6e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.68e-06	7.59e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.62e-06	7.41e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.58e-06	7.32e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.55e-06	7.23e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.55e-06	7.22e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.54e-06	7.2e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.54e-06	7.19e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.54e-06	7.19e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.46e-06	6.95e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.42e-06	6.85e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.41e-06	6.82e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.4e-06	6.8e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	2.4e-06	6.79e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.39e-06	6.78e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.37e-06	6.7e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.35e-06	6.65e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.35e-06	6.65e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.35e-06	6.64e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.32e-06	6.57e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.29e-06	6.49e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.29e-06	6.48e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.28e-06	6.45e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.28e-06	6.45e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.28e-06	6.45e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.28e-06	6.45e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.27e-06	6.44e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.22e-06	6.29e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.22e-06	6.28e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.21e-06	6.25e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.2e-06	6.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.2e-06	6.22e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.16e-06	6.13e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.16e-06	6.12e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.16e-06	6.11e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.1e-06	5.94e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.09e-06	5.91e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.08e-06	5.87e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.99e-06	5.64e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.98e-06	5.61e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.94e-06	5.5e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.93e-06	5.46e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.87e-06	5.3e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.86e-06	5.28e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.83e-06	5.18e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.81e-06	5.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.78e-06	5.04e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.78e-06	5.03e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.75e-06	4.96e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.72e-06	4.88e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.72e-06	4.88e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.64e-06	4.65e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.63e-06	4.63e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.63e-06	4.62e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.51e-06	4.26e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.48e-06	4.18e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.47e-06	4.16e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.42e-06	4.01e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.41e-06	3.99e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.36e-06	3.84e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.35e-06	3.81e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.24e-06	3.51e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.12e-06	3.16e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.64e-07	2.16e-06	CbGpPWpGaD
